Yingling Zhou

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Inflammatory Response

Monoclonal Antibody

Top Venues

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Limei Min, Xiaolu Wang, Anni Chen, Yingling Zhou, Yu-Chen Ge, Juanjuan Dai, Xiaofeng Chang, Wu Sun, Qin Liu, Xia Zhou, Manman Tian, Wentao Kong, Junmeng Zhu, Jie Shen, Baorui Liu, Ru-Tian Li
Design of a single-center, phase II trial to explore the efficacy and safety of 'R-ISV-RO' treatment in advanced tumors. Future oncology (London, England) 20 (17) (2024)
Limei Min, Xiaolu Wang, Anni Chen, Yingling Zhou, Yu-Chen Ge, Juanjuan Dai, Xiaofeng Chang, Wu Sun, Qin Liu, Xia Zhou, Manman Tian, Wentao Kong, Junmeng Zhu, Jie Shen, Baorui Liu, Ru-Tian Li
Design of a single-center, phase II trial to explore the efficacy and safety of 'R-ISV-RO' treatment in advanced tumors. Future oncology (London, England) 20 (17) (2024)
Limei Min, Xiaolu Wang, Anni Chen, Yingling Zhou, Yu-Chen Ge, Juanjuan Dai, Xiaofeng Chang, Wu Sun, Qin Liu, Xia Zhou, Manman Tian, Wentao Kong, Junmeng Zhu, Jie Shen, Baorui Liu, Ru-Tian Li
Design of a single-center, phase II trial to explore the efficacy and safety of 'R-ISV-RO' treatment in advanced tumors. Future oncology (London, England) (2024)
Limei Min, Xiaolu Wang, Anni Chen, Yingling Zhou, Yu-Chen Ge, Juanjuan Dai, Xiaofeng Chang, Wu Sun, Qin Liu, Xia Zhou, Manman Tian, Wentao Kong, Junmeng Zhu, Jie Shen, Baorui Liu, Ru-Tian Li
Design of a single-center, phase II trial to explore the efficacy and safety of 'R-ISV-RO' treatment in advanced tumors. Future oncology (London, England) 20 (17) (2024)
Limei Min, Xiaolu Wang, Anni Chen, Yingling Zhou, Yu-Chen Ge, Juanjuan Dai, Xiaofeng Chang, Wu Sun, Qin Liu, Xia Zhou, Manman Tian, Wentao Kong, Junmeng Zhu, Jie Shen, Baorui Liu, Ru-Tian Li
Design of a single-center, phase II trial to explore the efficacy and safety of 'R-ISV-RO' treatment in advanced tumors. Future oncology (London, England) (2024)